The molecular basis of ligand recognition by the melanocortin 4 receptor (MC4R) has not been fully defined. In this study, we investigated the molecular determinants of MC4R ligand binding, employing a large array of ligands, using three approaches. First, molecular modeling of the receptor was used to identify Phe284, in transmembrane (TM) 7, as a potential site of ligand interaction. Mutation of Phe284 to alanine reduced binding affinity and potency of peptides containing L-Phe by up to 71-fold but did not appreciably affect binding of linear peptides containing D-Phe, consistent with a hydrophobic interaction between the Phe7 of ␣-melanocyte-stimulating hormone and Phe284. Second, we examined the effect of a naturally occurring mutation in TM3 (I137T) that is linked to obesity. This mutation decreased affinity and potency of cyclic, rigid peptides but not more flexible peptides, consistent with an indirect effect of the mutation on the tertiary structure of the receptor. Third, we examined the residues that support ligand selectivity for the MC4R over the MC3R. Mutation of Ile125 (TM3) of the MC4R to the equivalent residue of the MC3R (phenylalanine) selectively decreased affinity and potency of MC4R-selective ligands. This effect was mirrored by the reciprocal MC3R mutation F157I. The magnitude of this effect indicates that this locus is not of major importance. However, it is considered that an isoleucine/phenylalanine mutation may affect the orientation of Asp122, which has been identified as a major determinant of ligand binding affinity. Thus, this study provides further characterization of the MC4R binding pocket.
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The melanocortin receptors are members of the seven transmembrane (TM) G protein-coupled receptor family. There are five melanocortin receptor subtypes cloned to date, MC1 through MC5, all of which couple to Gs to stimulate adenylate cyclase. These receptors are activated by a group of peptides derived from post-translational processing of the pro-opiomelanocortin gene transcript. These peptides include ␣-melanocyte-stimulating hormone (␣-MSH) and adrenocorticotropin hormone (ACTH), both of which contain the common amino acid sequence His6-Phe7-Arg8-Trp9 (Sahm et al., 1994; Haskell-Luevano et al., 1997) . Melanocortin receptor activation is modulated by two endogenous antagonists/inverse agonists, agouti and agouti-related protein (AGRP) (Lu et al., 1994; Ollmann et al., 1997) . AGRP is 132 amino acids in length but is thought to mimic the binding of the much smaller 13-amino acid agonist ␣-MSH through an Arg-PhePhe motif. This motif is found in the C-terminal half of the protein, and commonly, a truncated portion of the protein AGRP(87-132) is used in characterization studies. AGRP(87-132) exhibits the same melanocortin receptor binding selectivity as full-length AGRP and has been reported to act as a competitive antagonist (Yang et al., 1999) .
Recently, there has been great interest in the MC4 receptor, as it has been reported to be important in the regulation of feeding. MC4Ϫ/Ϫ mice exhibit hyperphagia and accelerated weight gain (Huszar et al., 1997) . Ectopically expressed AGRP results in an obese phenotype (Butler et al., 2001) . Furthermore, the MC4 receptor agonist MTII inhibits feeding in both mice models of hyperphagia and fasted mice (Fan et al., 1997) . It was also demonstrated that this effect could be blocked by the antagonist SHU9119, which when given alone was able to enhance nocturnal feeding. However, both MC3 and MC4 receptors are expressed at high levels in the brain, and MC3 receptor action in the regulation of food intake is unclear. MC3 receptor knockout mice exhibit increased fat mass but are not significantly overweight (Butler et al., 2000; Chen et al., 2000) . This indicates that the MC3 and MC4 receptors serve different roles in the regulation of energy homeostasis. Potential pharmaceutical benefit can be reaped from development of ligands that can discriminate between MC3 and MC4 receptors, and therefore, it is important to identify the molecular determinants of the receptor that enable MC4/MC3 receptor discrimination. A number of MC4-selective ligands have been developed, including the agonist peptide HfRWK (Bednarek et al., 1999) , the antagonist peptide M10 (Bednarek et al., 2001) , and the nonpeptide agonist tetrahydroisoquinoline (THIQ) (Van der Ploeg et al., 2002) (Table 1) . Conversely, ␥-MSH and a modification of the peptide ␥trp9 show some selectivity for the MC3 receptor over the MC4 receptor.
Earlier mutagenesis studies have already identified a number of important residues involved in ligand binding to the MC4 receptor (Yang et al., 2000; . These include an ionic interaction between melanocortin peptide residue Arg8 and aspartate residues 122 and 126 in TM3 and a hydrophobic interaction between melanocortin peptide residue Phe7 with aromatic residue Phe261 in TM6. A further phenylalanine residue in TM4 of the mouse MC4 receptor has also been proposed to interact with melanocortin peptide Phe7 residue ). However, the binding pocket of the melanocortin peptides and the endogenous antagonists is still not clearly defined.
In this study, we have taken three approaches to further define the molecular determinants of the MC4 receptor involved in ligand interaction. In the first approach, we have used molecular modeling to identify candidate residues of the receptor involved in ligand binding. Using this method, we identified Phe284 as a potential ligand binding site. Second, given the potential importance of the MC4 receptor in treating obesity, we have fully characterized the effect of a mutation in the receptor (I137T) reported to directly lead to obesity (Gu et al., 1999) . Finally, using sequence alignment and knowledge of the binding site, we have identified a residue that may account for some of the differences in the MC4 and MC3 receptor binding sites. In all cases, a large array of ligands have been used to define the effect of the mutation, allowing inferences in regard to effects on specific ligands and effects on specific residues, regions, or physical properties of the ligands. (Bednarek et al., 2001) , HfRWK (Bednarek et al., 1999) , and ␥trp9 were synthesized by solid-phase methodology on a Beckman Coulter 990 peptide synthesizer (Fullerton, CA) using t-N-tert-butoxycarbonyl-protected amino acids, and the assembled peptide was deprotected with hydrogen fluoride. The crude peptide products were purified by preparative high-performance liquid chromatography. All primers were synthesized and desalted by Invitrogen (Carlsbad, CA). The nonpeptide agonist THIQ ( Van der Ploeg et al., 2002) was synthesized by the Chemistry Department at Neurocrine. All other reagents were of the highest quality available.
Materials and Methods

Radiolabeled
Creation of MC4 and MC3 Receptor-Stable Cell Lines. HEK-293 cells were maintained in DMEM with 10% fetal calf serum. Wild-type receptor constructs in pcDNA3.1 were transfected using LipofectAMINE (Invitrogen). Stable receptor populations were generated using G418 (Invitrogen) selection (1 mg/ml).
Receptor Mutagenesis. Human MC4 or MC3 receptor cDNAs in pcDNA3.1 were used as a template for mutagenesis. Mutants were prepared using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). PCR reactions (95°C, 1 min; 52°C, 1 min; and 72°C, 16 min) were performed using Pfu polymerase and a complementary set of primers encoding the nucleotide mutation(s), TABLE 1 Amino acid sequence/structure of natural and synthetic melanocortin receptor ligands resulting in the desired amino acid residue change. Template DNA was nicked with DpnI, and mutant DNA was subcloned into competent TOP10 cells. Clones were sequenced using an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA), and clones containing the desired mutation were subcloned into the EcoRI/XhoI sites of a fresh pcDNA3.1 vector. Complete mutant MC4 receptor sequences were confirmed by DNA sequencing.
Transient Transfection. HEK-293 cells were maintained in DMEM with 10% fetal calf serum. Twenty-four hours prior to transfection, cells were seeded at 2 ϫ 10 6 cells/100-mm dish. Eight micrograms of mutant DNA were transfected using Polyfect (QIAGEN, Valencia, CA) according to the manufacturer's instructions. Cells were either harvested or assayed for cAMP accumulation after 48 h.
Membrane Preparation. Cells were washed once with phosphate-buffered saline. Then, 5 ml of ice-cold buffer (20 mM HEPES, 1 mM MgCl 2 , and 1 mM EDTA, pH 7.4) was used to disrupt the cell monolayer in each 100-mm dish. This was transferred to a Dounce glass/glass homogenizer. The cells were homogenized at 4°C by 40 strokes of the Dounce homogenizer. The homogenate was centrifuged for 10 min at 1,700g, and the supernatant was collected and centrifuged at 48,000g (4°C) for 1 h. The resulting pellet was resuspended in buffer, and aliquots were stored at Ϫ80°C. Protein concentration was determined using the Bio-Rad protein assay (Bio-Rad, Hercules, CA) using BSA as standard. Nonspecific binding was determined by the inclusion of 1 M SHU9119. The reaction was initiated by the addition of membranes, and the plates were incubated at 25°C for 2 h. The reaction was terminated by rapid filtration using a vacuum harvester with five 100-l washes of ice-cold wash buffer (25 mM HEPES, 1 mM MgCl 2 , 2.5 mM CaCl 2 , 0.1% BSA, and 500 mM NaCl, pH 7.0). The filters were soaked in 50 l of scintillation fluid, and the amount of radioactivity present was determined by liquid scintillation counting.
Ligand were incubated with 0.3 nM iodinated radioligand and various concentrations of competitor ligand, in duplicate, in a total volume of 100 l of buffer [25 mM HEPES, 1 mM MgCl 2 , 2.5 mM CaCl 2 , 0.5% BSA, and 1% Bacitracin (1 complete EDTA-free protease inhibitor tablet/50 ml), pH 7.0]. Nonspecific binding was determined by the inclusion of 1 M SHU9119. The reactions were initiated, incubated, and terminated as described above. The effect of guanine nucleotides on agonist binding was assessed by the addition of 30 M GTP␥S to the buffer.
cAMP Accumulation Assay. One day prior to experimentation, cells were plated at a density of 5 ϫ 10 3 cells/well in 96-well polylysine-coated plates, in DMEM lacking phenol red. On the day of experimentation, cells were preincubated with 1 mM isobutylmethylxanthine for 10 min. They were then stimulated with various concentrations of ligand (in DMEM containing 1 mM isobutylmethylxanthine) for 1 h. Cells were then lysed and cAMP quantified using the Tropix cAMP-Screen chemiluminescent enzyme-linked immunosorbent assay system (Applied Biosystems) according to the manufacturer's instructions.
Data Analysis. Data were analyzed using PRISM (GraphPad Software Inc., San Diego, CA), and statistical significance determined using Student's t tests. p Ͻ 0.05 determined statistical significance. K i values were determined from IC 50 values using the method of Cheng and Prusoff (1973) .
Results
Pharmacological Characterization of the MC4 Receptor Expressed Stably in HEK-293 Cells. Changes in ligand affinity observed in site-directed mutagenesis studies are subject to different interpretation depending on the conformation (i.e., activated or inactivated) of the receptor being studied. The MC4 receptor has not previously undergone a full in vitro pharmacological characterization to determine the potential affinity states present. Therefore, we determined this before proceeding with the mutagenesis experiments.
According to the extended ternary complex model (Samama et al., 1993) , ligands display different functional profiles because they differ in affinity for different receptor conformations. Agonists display a preference for the G proteincoupled form of the receptor, inverse agonists display a preference for the inactivated G protein-uncoupled form of the receptor, and antagonists do not discriminate between different receptor conformations. Different receptor states are usually detected using radioligand binding. , are available that can bind to the MC4 receptor. These ligands all bind specifically to membranes prepared from HEK-293 cells stably expressing the human MC4 (hMC4) receptor but not to membranes prepared from untransfected HEK-293 cells. These ligands all display different pharmacological profiles. In the cell line stably expressing the MC4 receptor used in this study, NDP-MSH is a full agonist ( (Fig. 3) . Affinity values for the competing ligands were similar versus all radioligands (Table 2) . Interestingly, whichever radioligand was used, competition binding curves for ligands, including agonists, were best fit by a one binding site model. This was an unexpected observation, since the ternary complex model (De Lean et al., 1980) predicts that agonists display a preference for receptors coupled to G protein, whereas antagonists do not discriminate between uncoupled receptors and those coupled to G protein. Consequently, competition curves involving an agonist and a radiolabeled antagonist commonly exhibit curves characterized by low Hill coefficients, from which two affinity constants can be generated.
MC4 Receptor Determinants of Ligand
The effect of receptor/G protein coupling on ligand binding affinity was further investigated, using GTP␥S to uncouple receptor from G protein (Gilman, 1987) . The affinity constants of antagonists and the agonists NDP-MSH and ACTH were unaffected by the inclusion of 30 M GTP␥S in the assay buffer, whereas the remaining agonists exhibited up to a 6-fold decrease in affinity in the presence of GTP␥S (Table  3 ). In addition, GTP␥S did not consistently increase the Hill coefficients of the agonist/[
125 I]SHU9119 competition curves. These findings suggest that the MC4 receptor population labeled by [
125 I]SHU9119 exists predominantly in an "active" conformation in the absence of GTP␥S, which is transformed to an inactive state with slightly lower affinity for certain agonists by GTP␥S. Thus, it was concluded that a single activated receptor population was being labeled in binding studies.
Mutagenesis Studies. A number of MC4 receptor residues have been mutated in this study and are summarized in Fig. 4A . Putative ligand-receptor interactions (Fig. 4B) were derived from homology molecular modeling of the human MC4 receptor based on the 2.8Å-resolution structure of rhodopsin (Palczewski et al., 2001) . This model predicted an ionic interaction between ␣-MSH and aspartate residues 122 and 126 in TM3 and a hydrophobic interaction between ␣-MSH and both Phe261 in TM6 and Phe284 in TM7. In addition to molecular modeling studies, further receptor mutations were systematically executed based on both previous characterization of the ligand binding site and sequence analysis looking at the differences between the MC3 and MC4 receptors.
All mutant receptors were transiently transfected into HEK-293 cells, ligand affinity was measured in competition analysis versus [
125 I]SHU9119, and agonist potency was measured in cAMP accumulation assays. Receptor expression levels were measured by [
125 I]SHU9119 saturation binding, and although expression levels were found to differ (Table 4), it was considered unlikely that this had any influence on the results obtained. In addition, no marked differences in basal cAMP accumulation were observed in the functional assays, indicating that none of the mutant receptors displayed constitutive activity.
Hydrophobic Interaction with TM4, TM6, and TM7. Both the Phe7 and Trp9 residues of ␣-MSH have been reported to be important in binding to the MC4 receptor (Yang et al., 2000) . To ascertain which residues of the MC4 receptor interact with ␣-MSH, a number of phenylalanine residues were mutated. First, a F261A mutation was characterized; this exhibited similar binding parameters to those previously reported (Yang et al., 2000) , with a large loss of affinity for ␣-MSH (Ͼ100-fold) but little loss in affinity for NDP-MSH (2-fold) and AGRP(83-132) (3.5-fold) (Fig. 5 and Table 4 ). Additionally, we discovered that the binding affinity of SHU9119 was not significantly decreased by the F261A mutation (p Ͼ 0.05, Student's t test), but the binding of the small-molecule agonist THIQ was, with a 66-fold decrease in affinity (p Ͻ 0.05, Student's t test). Consistent with previous literature and binding data, the F261A receptor exhibited decreased agonist potency and discriminated between ␣-MSH and NDP-MSH (Fig. 6 and Table 5 ). The potency of NDP-MSH was only marginally affected, but an EC 50 value could not be determined for ␣-MSH. Furthermore, the smallmolecule agonist THIQ showed a 55-fold decrease in potency (p Ͻ 0.05, Student's t test). The efficacies of the agonists were not significantly affected by this mutation (Table 6 ).
Our molecular model predicts that Phe284 could interact with ␣-MSH. Therefore, we mutated Phe284 to an alanine and tested the effect of this mutation on ligand binding and agonist function. Ligand binding to the F284A receptor was severely affected, with a 2.8-to 71-fold decrease in ligand affinity. This reached significance (p Ͻ 0.05, Student's t test) for all ligands except NDP-MSH. In fact, similarly to the D122A and F261A mutant receptors, substitution of phenylalanine 284 with an alanine led to clear discrimination between NDP-MSH and the endogenous peptides ␣-MSH and ACTH, as the affinities of these ligands showed the least (2.8-fold) and greatest (71-and Ͼ33-fold) decrease, respectively. The F284A mutation exhibited the greatest decreases (M10, 16-fold) in antagonist binding affinity observed in this study. Functional assay data obtained with the F284A receptor mimicked binding data in that the potency of all agonists with the exception of NDP-MSH was affected, with significant (p Ͻ 0.05, Student's t test) decreases in potency ranging from 3.5-(MTII) to 21-fold (ACTH). However, the efficacies of the various agonists were largely unaffected by this mutation.
Phe184 is conserved in MC1, 3, 4, and 5 receptors but corresponds to a methionine in the MC2 receptor. The phenylalanine-to-methionine mutation F184M did not reduce the binding affinity of any of the ligands tested (p Ͼ 0.05, 
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Student's t test); instead, a slight increase in affinity for M10 was observed. There was also no significant change in the efficacy or potency of any of the agonists tested (p Ͼ 0.05, Student's t test). Interaction with TM3. MC4 receptors have been implicated in obesity, and a number of studies have suggested that mutations in the MC4 receptor may be one of the causes of human obesity. Therefore, we decided to further characterize a TM3 mutation found in obese subjects (I137T) (Gu et al., 1999) . The I137T mutation significantly decreased the binding of most ligands, with the exception of ␣-MSH and NDP-MSH, with decreases between 1.8-and 4.8-fold compared with wild-type MC4 receptor (p Ͻ 0.05, Student's t test). The I137T mutation did not significantly affect efficacy but caused a decrease in potency of most agonists, with THIQ, HfRWK, and MTII showing significant differences of between 3.7-and 9.6-fold (p Ͻ 0.05, Student's t test).
Previous mutagenesis studies (Yang et al., 2000; HaskellLuevano et al., 2001 ) have implicated the aspartate residues in TM3 (122 and 126) as being important in melanocortin peptide binding. In this study, the D122A mutant receptor exhibited the expected change in binding parameters, with a much greater loss of affinity for ␣-MSH (Ͼ100-fold) than NDP-MSH (6-fold). Furthermore, the binding affinities of the inverse agonist AGRP(83-132) and the antagonist SHU9119 were all significantly decreased (p Ͻ 0.05, Student's t test). We also demonstrated that the small-molecule agonist THIQ interacts with Asp122, as substitution of this residue with an alanine decreased the binding affinity 66-fold. Agonist potency was also decreased by the D122A mutation; an EC 50 value for ␣-MSH could not be determined, although a functional response was seen at 10 M. The potency of THIQ was also significantly decreased (p Ͻ 0.05, Student's t test), but, consistent with the binding data, the potency of NDP-MSH was not markedly affected.
A number of ligands have been developed that can discriminate between the MC4 and MC3 receptors. Since the con- Fig. 4 . A, two-dimensional representation of the seven-TM structure of the hMC4 receptor. The TM residues mutated in this study are denoted by gray highlighting. B, homology modeling of the hMC4 receptor based on the 2.8 Å resolution structure of rhodopsin (Palczewski et al., 2001) . served aspartate residues (Asp122 and Asp126 in MC4R and Asp117 and Asp121 in MC1R) are critical for ␣-MSH binding and function in both MC4 (Yang et al., 2000; ) and MC1 receptors , it is probable that analogous residues in the MC3 receptor (Asp154 and Asp158) play a role in ␣-MSH binding to the MC3 receptor. It therefore follows that the positioning of the aspartate residues may play a role in determining the MC3/ MC4 selectivity of ligands. We observed that between these two key residues, an isoleucine is present in the MC4 receptor (Ile125), and a phenylalanine is present in the MC3 receptor (Phe157). Due to the difference in bulk of these residues, it was hypothesized that they may affect the interaction of ligands with the aspartate residues. Hence, the MC4 receptor mutant I125F and the reverse MC3 receptor mutant F157I were made. Competition analysis revealed that the I125F mutation in the MC4 receptor resulted in a 2-to 5-fold decrease in the affinity of the MC4 receptor-selective ligands, THIQ, HfRWK, MTII, and SHU9119. This was significant in the cases of THIQ, HfRWK, and SHU9119 (p Ͻ 0.05, Student's t test). The binding affinities of nonselective and MC3 receptor-selective ligands were not significantly affected, indicating that the receptor conformation was not appreciably affected by the mutation. The MC3 receptor mutant F157I showed a significant increase in affinity for the MC4 receptor-selective ligands HfRWK (5.9-fold) and MTII (3.4-fold) (p Ͻ 0.05, Student's t test). The affinity of ␣-MSH was also significantly increased. Although the affinity of ␣-MSH is not significantly different between MC3 and MC4 receptors, there is a trend for its affinity to be higher at the MC4 receptor. Functional data mimicked binding data, with the I125F mutation significantly (p Ͻ 0.05, Student's t test) decreasing the potency of the MC4 receptor-selective agonists THIQ (6.2-fold), HfRWK (7.2-fold), and MTII (2.5-fold). MC3 receptor-selective or nonselective agonists showed no change in potency, and none of the agonists showed a marked change in efficacy. The MC3 receptor mutant F157I mirrored these results. Compared with the wild-type MC3 receptor, F157I showed an increase in potency of MC4 receptor-selective agonists. This reached significance in the case of MTII (4.4-fold) and HfRWK (6.4-fold) (p Ͻ 0.05, Student's t test). There was also a 3-fold increase in ␣-MSH potency. The F157I mutant receptor also exhibited a decrease in the maximal response (E max ) of ␥-MSH and ␥trp9 compared with the wild-type MC3 receptor (p Ͻ 0.05, Student's t test).
Discussion
In this study, we used site-directed mutagenesis to further define the MC4 receptor binding site and to determine which residues contribute to the selectivity between the MC3 and MC4 receptors. We examined the binding and function of a large range of peptides and a small molecule to define differences in binding between similar compounds. We also investigated some of the pharmacological properties of this receptor, in particular, the sensitivity of ligands to GTP␥S, to gain some insight into the process of receptor activation.
In agreement with previous literature Nijenhuis et al., 2001) , AGRP(83-132) was an inverse agonist at the MC4 receptor. NDP-MSH was a full agonist, and SHU9119 was a very weak partial agonist. The MC4 receptor is largely guanine nucleotide insensitive. In [ 125 I]SHU9119 displacement assays, a one binding site model was preferred in both the absence and presence of GTP␥S, and agonists only displayed a minimal decrease in affinity in the presence of GTP␥S. In particular, NDP-MSH binding was not detectably affected by GTP␥S. This is consistent with the saturation data; the B max of [
125 I]NDP-MSH was equivalent (Siehler et al., 1999) and the D 2 dopamine receptor (Cordeaux et al., 2001) ; at both of these receptors, agonists differ in their sensitivity to guanine nucleotides. It has been proposed that guanine nucleotide-insensitive agonists are able to stabilize a conformation of the receptor, which is close to the conformation of the active receptor/G protein complex, so that there is little energy gain in coupling to the G protein (Strange, 1999) . Overall, it is concluded from these data that a single activated receptor population is being labeled. This simplifies interpretation of the site-directed mutagenesis binding data, as changes in ligand affinity likely affect receptor/ligand interaction, be it directly or indirectly, rather than the receptor state.
The Previous evidence for MC4 receptor dimerization is seen in a report demonstrating that palmitoylated peptides derived from the third intracellular loop of the MC4 receptor acted as agonists in cells expressing the MC4 receptor (Covic et al., 2002) . Furthermore, the high-resolution NMR structure of AGRP implies that there may be more than one site that interacts with the receptor (McNulty et al., 2001) . Following this assumption, the complete inhibition of [ 125 I]SHU9119 binding by AGRP(83-132) may imply that the receptors are dimerized. Nevertheless, little evidence for this phenomenon was observed in ligand binding. NDP-MSH, SHU9119, and AGRP all acted competitively against each other, and ligands displayed similar affinity in competition studies against the different radioligands, which is consistent with all three radioligands binding to the same site.
Analysis of the expression levels of the MC4 receptor mutants revealed large variation. However, an increase in receptor expression level did not correlate with an increase in agonist affinity or potency, which may have been predicted. It is considered unlikely that the mutations themselves have affected this correlation, as the F184M, F261A, and D122A mutant receptors did not display increased agonist potencies or binding affinities despite their higher expression levels. In addition, other mutations in the MC4 receptor (S190A, S191A, and F267L) showed no appreciable change in agonist affinity or potency relative to the wild-type MC4 receptor, despite the fact that the S190A mutant was expressed at a 10-fold lower level (data not shown). Furthermore, studies in our laboratory have shown that increasing the expression level of the MC4 receptor does not lead to an increase in agonist potency (M. Cismowski, unpublished data). It is, therefore, believed that the differences in expression level do not invalidate the comparisons between wild-type and mutated receptors.
Data obtained in this mutagenesis study provide evidence of a direct interaction between the Phe7 residue of ␣-MSH with both Phe261 and Phe284. The F261A mutant data agreed with previous literature (Yang et al., 2000; HaskellLuevano et al., 2001) , with dramatic decreases in ␣-MSH, but not NDP-MSH, binding affinity and potency. Data obtained at F284A followed this trend, with ␣-MSH and ACTH, but not NDP-MSH, exhibiting large decreases in binding affinity and potency. NDP-MSH primarily differs from ␣-MSH and ACTH by the stereochemistry of the Phe7 residue, indicating that it is this residue that causes the selective decrease in affinity for ␣-MSH compared with NDP-MSH. The binding affinities of cyclic peptides that either contain D-Phe or D-Nal in the Phe7 position were also decreased by the Phe284 mutation, although not to the extent of the linear phenylalanine-containing peptides. These results demonstrate how subtle differences in ligand structure may lead to binding in slightly different orientations. We also established that the binding affinity and potency of the small-molecule agonist THIQ were both decreased by the F284A and F261A mutations. Combining this with the D122A data demonstrates that this small molecule is binding in a similar orientation to ␣-MSH. The binding affinity of the antagonist AGRP(83-132) was also decreased by the F284A mutation, indicating that it shares an overlapping binding pocket with the melanocortin peptides. The greater changes in agonist binding affinity versus potency at the F284A mutant receptor, and the lack of effect of the F261A mutation on antagonist binding, support the conclusion that this region is not important in determining receptor activation. This is in accordance with the recent findings of Yang et al. (2002) , who report that Leu133 (TM3) of the MC4 receptor is critical for the antagonist activity of SHU9119.
The TM3 mutation I137T, which is found in obese subjects (Gu et al., 1999) , displayed decreased affinity and potency for Potency of melanocortin agonists at wild-type and mutant MC4 and MC3 receptors measured using cAMP accumulation most MC4 receptor ligands. Because this residue is positioned deep within the TM3 helix, we suggest that the effect of this mutation may be a consequence of nonspecific alteration of the receptor tertiary structure. Consistent with this notion, the binding of the more rigid cyclic peptides was affected, whereas that of the more flexible linear peptides was not.
It has previously been proposed that there is an ionic interaction between the Arg8 of melanocortin peptides and the aspartate residues in TM3 (Yang et al., 2000; HaskellLuevano et al., 2001) . The Asp122 mutation made in this study significantly affected the binding of all compounds except NDP-MSH, which is consistent with the above hypothesis. This study also demonstrated that the spacing between the two aspartate residues plays a small role in determining MC3/MC4 receptor selectivity. Asp122 and Asp126 theoretically both face into the binding pocket, since three to four amino acids is approximately one full turn in the presumed ␣-helical structure of the TM domains. One would anticipate that the difference in bulk of the isoleucine (MC4) versus phenylalanine (MC3) separating these residues would lead to a slightly different orientation of the aspartate residues in the binding pocket. Accordingly, the MC4 receptor mutant I125F and the MC3 receptor mutant F157I displayed a respective decrease or increase in affinity and potency for most MC4 receptor-selective ligands, although the small shifts in affinity and potency values indicate that this locus is of minimal importance in determining receptor selectivity.
Overall, the data herein highlight potentially important differences between the ligand binding site of the human MC4 receptor and that of other melanocortin receptor subtypes and species variants of the MC4 receptor. Specifically, a mutation analogous to F284A in the hMC1 receptor had no effect on binding or function . The data presented in this study show that ligand binding and function was generally unaltered by the F184M mutation, which would disrupt any hydrophobic interactions between the phenylalanine and the melanocortin peptides. Conversely, mutation of an analogous residue in the mouse MC4 receptor to a serine drastically decreased peptide binding and agonist function , leading to the hypothesis that the hydrophobic binding pocket for Phe7 was formed between TMs 6 and 4 rather than TMs 6 and 7, as indicated by our data. It is considered that a F184S mutation repulses the aromatic residues in the melanocortin ligands; in accordance with this reasoning, an analogous mouse F184L mutation did not produce such a drastic decrease in ligand affinity .
In summary, this study demonstrates some unique pharmacological properties of the MC4 receptor. Agonists exhibit little sensitivity to guanine nucleotides, and the agonist NDP-MSH appears to label all forms of the receptor with the same affinity. We have demonstrated that the MC4 receptor residue Ile125 has a role in determining ligand selectivity between the MC3 and MC4 receptors. This leads to the hypothesis that conserved residues in the melanocortin receptors are involved in ligand binding, but differences in their positioning due to differences in receptor structure lead to ligand selectivity for one receptor over another. We have also determined that Phe284 in TM7 forms a hydrophobic pocket with Phe261 in TM6, in which the Phe7 residue of ␣-MSH binds.
